23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter ...

The DNA-testing company is exploring its options, including a business combination and the sale of some or all of its assets.

A pioneer in genetic heritage services, 23andMe has seen much of its share price wiped out in the past year as it struggles ...

Me (ME) forms special board committee to explore strategic alternatives, including sale, restructuring, or business ...

Holding released a new polygenic risk score report on the genetics of osteoporosis for 23andMe+ Premium members. The report ...

The testing company ended last year with $79 million and told investors it will need to raise money to fund its operations ...

23andMe Holding Co. ( ME, Financials) announced that its board's Special Committee is reviewing strategic alternatives, ...

By the 2023 fiscal year, 23andMe had reported a net loss of $312 million and its individual share price has plummeted a ...

23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year.

Me (ME) ended December 31, 2024 with cash and cash equivalents of $79.4M, compared to $126.6M as of September 30, 2024 and $216.5M as of ...

Manhattan Associates' 2025 outlook missed estimates. The provider of supply-chain and omnichannel-commerce solutions said it expects adjusted per-share earnings of $4.45 to $4.55 on revenue of $1.06 ...

The Special Committee of the Board of Directors of 23andMe Holding Co. (Nasdaq: ME) ("23andMe" or the "Company"), a leading human genetics company ...